Objective: Elastography has become the standard of care of diagnostic approaches for liver disease, particularly when dealing with hepatitis C. There areno studies in the inner-city populations of Newark, New Jersey, that describe the comparison of noninvasive markers, such as FibroScan andaminotransferase-to-platelet ratio index (APRI) scoring.
Methods: Using a chart review method, we used a case-control study method of gathering and analyzing the data, using < or = 0.05 as a significant variable.
Results: The outcome of this study indicates that the FibroScan may be a better marker than the APRI score for the staging of liver disease when a patient has hepatitis B or C with or without HIV/AIDS.
Conclusions: This may be a benchmark study to further enhance our understanging of the utility of the fibroscan.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555234 | PMC |
http://dx.doi.org/10.4103/jgid.jgid_10_16 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!